Vesting

Kaizen Discovery Grants Stock Options

Retrieved on: 
Thursday, April 29, 2021

b'Vancouver, British Columbia--(Newsfile Corp. - April 29, 2021) - Kaizen Discovery Inc. (TSXV: KZD) (otherwise "Kaizen" or "the Company") announces today that, pursuant to its Stock Option Plan, it has granted incentive stock options to certain employees to purchase up to an aggregate of 909,090 common shares in the capital stock of the company.\nThe options are exercisable at a price of $0.055 per share and will vest 33 1/3% six (6) months after the date of the grant, with an additional 33 1/3% vesting twelve (12) months after the date and the remaining 33 1/3% vesting two (2) years after the date of grant.

Key Points: 
  • b'Vancouver, British Columbia--(Newsfile Corp. - April 29, 2021) - Kaizen Discovery Inc. (TSXV: KZD) (otherwise "Kaizen" or "the Company") announces today that, pursuant to its Stock Option Plan, it has granted incentive stock options to certain employees to purchase up to an aggregate of 909,090 common shares in the capital stock of the company.\nThe options are exercisable at a price of $0.055 per share and will vest 33 1/3% six (6) months after the date of the grant, with an additional 33 1/3% vesting twelve (12) months after the date and the remaining 33 1/3% vesting two (2) years after the date of grant.
  • The options expire on April 28, 2026.\nKaizen is a Canadian mineral exploration and development company with exploration projects in Peru and Canada.
  • More information on Kaizen is available at www.kaizendiscovery.com\n'

Bear Creek Grants Long Term Incentive Awards

Retrieved on: 
Monday, April 26, 2021

b'Vancouver, British Columbia--(Newsfile Corp. - April 26, 2021) - Bear Creek Mining Corporation (TSXV: BCM) (OTCQX: BCEKF) (BVL: BCM) ("Bear Creek" or the "Company") announces that its Board of Directors has authorized and approved the grant of a cumulative total of 1,000,000 Deferred Share Units (the "DSUs") to directors and officers the Company, including an employee performing investor relations activities.

Key Points: 
  • b'Vancouver, British Columbia--(Newsfile Corp. - April 26, 2021) - Bear Creek Mining Corporation (TSXV: BCM) (OTCQX: BCEKF) (BVL: BCM) ("Bear Creek" or the "Company") announces that its Board of Directors has authorized and approved the grant of a cumulative total of 1,000,000 Deferred Share Units (the "DSUs") to directors and officers the Company, including an employee performing investor relations activities.
  • This grant of DSUs is made pursuant to the Company\'s Long Term Incentive Plan (the "LTIP"), which was approved by shareholders on June 2, 2016.
  • The DSUs are subject to vesting provisions as detailed in the LTIP.\nOn behalf of the Board of Directors,\n'

New long-term share-based incentive program

Retrieved on: 
Thursday, April 22, 2021

The vested RSUs can only be exercised within four months after the expiration of the total vesting period for RSUs.

Key Points: 
  • The vested RSUs can only be exercised within four months after the expiration of the total vesting period for RSUs.
  • Any vested PSUs can only be exercised within four months after the expiration of the vesting period for PSUs.
  • Arimoclomol, the company\xe2\x80\x99s lead candidate, is in clinical development for Niemann-Pick disease type C (NPC), Amyotrophic Lateral Sclerosis (ALS), and Gaucher disease.
  • Arimoclomol is administered orally and has now been studied in seven phase 1, four phase 2 and one pivotal phase 2/3 trial.

Translate Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Tuesday, April 20, 2021

These grants were made pursuant to the Company\xe2\x80\x99s 2021 Inducement Stock Incentive Plan, were approved by the Company\xe2\x80\x99s board of directors, and were made as a material inducement to his acceptance of employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4) as a component of his employment compensation.\nThe stock options have an exercise price of $19.23 per share, equal to the closing price of Translate Bio\xe2\x80\x99s common stock on April 19, 2021.

Key Points: 
  • These grants were made pursuant to the Company\xe2\x80\x99s 2021 Inducement Stock Incentive Plan, were approved by the Company\xe2\x80\x99s board of directors, and were made as a material inducement to his acceptance of employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4) as a component of his employment compensation.\nThe stock options have an exercise price of $19.23 per share, equal to the closing price of Translate Bio\xe2\x80\x99s common stock on April 19, 2021.
  • Each stock option has a ten year term and vests over four years, with 25% of the shares underlying the option vesting on April 19, 2022 and in thirty-six equal monthly installments thereafter as to the remaining shares.
  • The vesting of each grant is subject to Brendan Smith\xe2\x80\x99s continued service with the Company through the applicable vesting date.
  • For more information about the Company, please visit www.translate.bio or on Twitter at @TranslateBio.\n'

Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Monday, April 19, 2021

b"NEW YORK, April 19, 2021 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical stage company developing transformative therapies for the treatment of cancer and rare diseases with significant unmet needs, today announced the grants of inducement non-qualified stock options to purchase an aggregate of 120,000 shares of common stock to Mart\xc3\xadn Sebastian Olivo, M.D., Protara\xe2\x80\x99s newly appointed Chief Medical Officer.\nEach stock option has an exercise price per share equal to $15.30 per share, Protara\xe2\x80\x99s closing trading price on April 19, 2021, the grant date, and will vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of the individual\xe2\x80\x99s applicable vesting commencement date and 1/36th of the underlying shares vesting monthly thereafter over 36 months subject to the new employee's continued service relationship with Protara through the applicable vesting dates.\nProtara is committed to identifying and advancing transformative therapies for people with cancer and rare diseases with limited treatment options.

Key Points: 
  • b"NEW YORK, April 19, 2021 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical stage company developing transformative therapies for the treatment of cancer and rare diseases with significant unmet needs, today announced the grants of inducement non-qualified stock options to purchase an aggregate of 120,000 shares of common stock to Mart\xc3\xadn Sebastian Olivo, M.D., Protara\xe2\x80\x99s newly appointed Chief Medical Officer.\nEach stock option has an exercise price per share equal to $15.30 per share, Protara\xe2\x80\x99s closing trading price on April 19, 2021, the grant date, and will vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of the individual\xe2\x80\x99s applicable vesting commencement date and 1/36th of the underlying shares vesting monthly thereafter over 36 months subject to the new employee's continued service relationship with Protara through the applicable vesting dates.\nProtara is committed to identifying and advancing transformative therapies for people with cancer and rare diseases with limited treatment options.
  • Protara\xe2\x80\x99s portfolio includes its lead program, TARA-002, an investigational cell-based therapy being developed for the treatment of non-muscle invasive bladder cancer and lymphatic malformations, and IV Choline Chloride, an investigational phospholipid substrate replacement therapy for the treatment of intestinal failure-associated liver disease.
  • For more information, visit www.protaratx.com.\n"

Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Thursday, April 22, 2021

The stock options have a 10-year term and vest over four years, with 12.5% of the shares underlying the options vesting on the six-month anniversary of commencement of employment and the remaining shares vesting over the following 42 months in equal installments of whole shares, subject to continued employment with Geron through the applicable vesting dates.

Key Points: 
  • The stock options have a 10-year term and vest over four years, with 12.5% of the shares underlying the options vesting on the six-month anniversary of commencement of employment and the remaining shares vesting over the following 42 months in equal installments of whole shares, subject to continued employment with Geron through the applicable vesting dates.
  • The options were granted as material inducements to employment in accordance with Nasdaq Listing Rule 5635(c)(4) and are subject to the terms and conditions of the stock option agreements covering the grants and Geron\xe2\x80\x99s 2018 Inducement Award Plan, which was adopted December 14, 2018 and provides for the granting of stock options to new employees.\nGeron is a late-stage clinical biopharmaceutical company focused on the development and potential commercialization of a first-in-class telomerase inhibitor, imetelstat, in hematologic myeloid malignancies.
  • The Company currently is conducting two Phase 3 clinical trials: IMerge in lower risk myelodysplastic syndromes and IMpactMF in refractory myelofibrosis.
  • For more information about Geron, visit www.geron.com .\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210422005280/en/\n'

CTI BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Thursday, April 22, 2021

The equity awards were approved on April 21, 2021, in accordance with Nasdaq Listing Rule 5635(c)(4).\nThe employees received options to purchase an aggregate of 80,000 shares of CTI BioPharma common stock.

Key Points: 
  • The equity awards were approved on April 21, 2021, in accordance with Nasdaq Listing Rule 5635(c)(4).\nThe employees received options to purchase an aggregate of 80,000 shares of CTI BioPharma common stock.
  • The options will be issued upon each employee\'s commencement of employment (the "Grant Date"), and all stock options included within the equity inducement awards will have an exercise price equal to the closing price of CTI BioPharma common stock on each respective Grant Date.
  • One-fourth of the options will vest on each anniversary of the employee\'s Grant Date, subject to the employee\'s continued employment with CTI BioPharma on such vesting dates.
  • In addition, we have recently started developing pacritinib for use in hospitalized patients with severe COVID-19, in response to the COVID-19 pandemic.

Brooklyn ImmunoTherapeutics Reports Inducement Grants

Retrieved on: 
Monday, April 19, 2021

The Milestone Option will have a per share exercise price equal to the closing price of a share of Brooklyn\xe2\x80\x99s common stock on the NYSE American Stock Exchange on 16 April 2021.

Key Points: 
  • The Milestone Option will have a per share exercise price equal to the closing price of a share of Brooklyn\xe2\x80\x99s common stock on the NYSE American Stock Exchange on 16 April 2021.
  • This milestone is subject to Dr. Federoff\xe2\x80\x99s continuous service with Brooklyn through such vesting date.\nThe unvested portion of the Time-Based Option and the Milestone Option will terminate upon the termination of Dr. Federoff\xe2\x80\x99s employment with Brooklyn for any reason, subject to certain vesting acceleration provisions upon a qualifying termination, as described in his employment agreement with Brooklyn.
  • In a Phase 2A clinical trial in head and neck cancer, IRX-2 demonstrated an overall survival benefit.
  • Additional studies are either underway or planned in other solid tumor cancer indications.\nFor more information about Brooklyn and its clinical programs, please visit www.BrooklynITx.com .\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210419005826/en/\n'

Translate Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Wednesday, April 7, 2021

These grants were made pursuant to the Companys 2021 Inducement Stock Incentive Plan, were approved by the Companys Inducement Grant Subcommittee of the board of directors, and were made as a material inducement to each employees acceptance of employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4) as a component of his or her employment compensation.

Key Points: 
  • These grants were made pursuant to the Companys 2021 Inducement Stock Incentive Plan, were approved by the Companys Inducement Grant Subcommittee of the board of directors, and were made as a material inducement to each employees acceptance of employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4) as a component of his or her employment compensation.
  • The stock options have an exercise price of $16.82 per share, equal to the closing price of Translate Bios common stock on April 5, 2021.
  • The vesting of each grant is subject to the employees continued service with the Company through the applicable vesting date.
  • The inducement grants are subject to the terms and conditions of award agreements covering the grants and the Companys 2021 Inducement Stock Incentive Plan.

Genel Energy PLC: Director/PDMR Shareholding

Retrieved on: 
Wednesday, April 7, 2021

PSP awards granted to PDMRs in the UK were made in the form of nil-cost options, which become exercisable following the end of a three-year performance period, subject to the satisfaction of performance targets.

Key Points: 
  • PSP awards granted to PDMRs in the UK were made in the form of nil-cost options, which become exercisable following the end of a three-year performance period, subject to the satisfaction of performance targets.
  • Options are then exercisable until the tenth anniversary of the date of grant.
  • The PSP performance period will run from 6 April 2021 to 5 April 2024.
  • Following vesting, shares granted under the PSP are subject to the Company's retention policy under which Executive Committee members are required to retain shares for an additional two years.